⏳ Fetching live dividend data...
Home › Calculator › WINTW Dividend Calculator 2026
Windtree Therapeutics, Inc. · OTC
Price: $0.00 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in WINTW → $6.11065630005083e+39M in 10 years · $509,220,612,408,937,700,000,000,000,000,000,000,000,000,000.00/month
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical company primarily focused on developing innovative therapies for acute cardiovascular conditions. Its robust pipeline features several key therapeutic candidates at various clinical stages: Istaroxime, their flagship compound, is currently undergoing Phase 2b clinical trials for acute decompensated heart failure and Phase 2a trials for early cardiogenic shock. Beyond cardiovascular indications, Windtree is advancing two surfactant-based therapies: AEROSURF, an aerosolized KL4 surfactant, is in Phase 2b for respiratory distress syndrome in premature infants. Surfaxin, a lyophilized KL4 surfactant, is in Phase 2a trials addressing lung injury associated with COVID-19. Rostafuroxin is another asset, currently in Phase 2b trials for genetically linked hypertension. Additionally, the company is exploring an oral and intravenous SERCA2a activator in preclinical studies, targeting both chronic and acute forms of heart failure. Windtree actively engages in strategic collaborations to bolster its research and development efforts. Partnerships include scientific cooperation with Chang Gung University focusing on cardiovascular aspects of SERCA2a, and a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds designed for chronic and acute human heart failure. Further alliances comprise a strategic partnership with Laboratorios del Dr. Esteve, S.A. for the global development, commercialization, and sales of its KL4 surfactant product portfolio, and an agreement with Battelle Memorial Institute specifically for the advancement of its ADS technology, crucial for their Phase III program. Tracing its origins back to 1992, the company initially operated as Discovery Laboratories, Inc. before rebranding as Windtree Therapeutics, Inc. in April 2016. Its corporate headquarters are situated in Warrington, Pennsylvania.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open WINTW position with:
Real after-tax yield depends on where you live and how you hold WINTW.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 66666.67% | 66663.87% | $6,666,667 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 56666.67% | 56663.87% | $5,666,667 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 53333.34% | 53330.54% | $5,333,334 / yr |
| 🇬🇧 UK ISA | 0% | 66666.67% | 66663.87% | $6,666,667 / yr |
| 🇬🇧 UK Taxable | 8.75% | 60833.34% | 60830.54% | $6,083,334 / yr |
| 🇨🇦 TFSA | 0% | 66666.67% | 66663.87% | $6,666,667 / yr |
| 🇨🇦 CA Taxable | 25% | 50000.00% | 49997.20% | $5,000,000 / yr |
| 🇦🇺 Super (pension) | 15% | 56666.67% | 56663.87% | $5,666,667 / yr |
| 🇦🇺 AU Taxable | 30% | 46666.67% | 46663.87% | $4,666,667 / yr |
| 🇩🇪 DE Taxable | 26.375% | 49083.34% | 49080.54% | $4,908,334 / yr |
| 🇫🇷 FR Taxable | 30% | 46666.67% | 46663.87% | $4,666,667 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
WINTW pays quarterly — 4 times per year. Next ex-div: TBD.
How WINTW compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for WINTW sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Buy | 2024-10-08 | 5,431 | $0.91 | $4.9K | ||
| A-Award | 2024-07-22 | 2,674 | $4.11 | $11.0K | ||
| A-Award | 2024-07-22 | 13 | — | — | ||
| A-Award | 2024-07-22 | 4,011 | $4.11 | $16.5K | ||
| A-Award | 2024-07-22 | 19 | — | — | ||
| Buy | 2023-09-27 | 2,500 | $1.02 | $2.5K | ||
| Buy | 2023-09-26 | 2,500 | $0.90 | $2.3K | ||
| Other | 2023-08-24 | 372 | $51.00 | $19.0K | ||
| Other | 2023-08-24 | 200 | $592.50 | $118.5K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the WINTW dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →